JP2019536798A - シャシャンボ実の抽出物を含む憂鬱症予防及び改善用健康機能性食品組成物 - Google Patents
シャシャンボ実の抽出物を含む憂鬱症予防及び改善用健康機能性食品組成物 Download PDFInfo
- Publication number
- JP2019536798A JP2019536798A JP2019529558A JP2019529558A JP2019536798A JP 2019536798 A JP2019536798 A JP 2019536798A JP 2019529558 A JP2019529558 A JP 2019529558A JP 2019529558 A JP2019529558 A JP 2019529558A JP 2019536798 A JP2019536798 A JP 2019536798A
- Authority
- JP
- Japan
- Prior art keywords
- shashanbo
- extract
- functional food
- preventing
- depression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000005480 Vaccinium bracteatum Nutrition 0.000 title claims abstract description 87
- 244000287839 Vaccinium bracteatum Species 0.000 title claims abstract description 87
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 235000013305 food Nutrition 0.000 title description 2
- 235000013376 functional food Nutrition 0.000 claims abstract description 16
- 230000036541 health Effects 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 235000012511 Vaccinium Nutrition 0.000 claims description 5
- 241000736767 Vaccinium Species 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000007901 soft capsule Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 210000003813 thumb Anatomy 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 31
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 15
- 238000010586 diagram Methods 0.000 abstract description 5
- 230000001988 toxicity Effects 0.000 abstract description 4
- 231100000419 toxicity Toxicity 0.000 abstract description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 108
- 210000004027 cell Anatomy 0.000 description 60
- 235000013399 edible fruits Nutrition 0.000 description 36
- 239000011575 calcium Substances 0.000 description 35
- 230000003834 intracellular effect Effects 0.000 description 31
- 235000021028 berry Nutrition 0.000 description 30
- 108020003175 receptors Proteins 0.000 description 26
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 17
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 17
- 229960002748 norepinephrine Drugs 0.000 description 17
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 17
- 102000005962 receptors Human genes 0.000 description 17
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 16
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 16
- 231100000135 cytotoxicity Toxicity 0.000 description 15
- 230000003013 cytotoxicity Effects 0.000 description 15
- 229940076279 serotonin Drugs 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- KTGRHKOEFSJQNS-BDQAORGHSA-N (1s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;oxalic acid Chemical compound OC(=O)C(O)=O.C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 KTGRHKOEFSJQNS-BDQAORGHSA-N 0.000 description 12
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 12
- 229960005086 escitalopram oxalate Drugs 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000001430 anti-depressive effect Effects 0.000 description 10
- 210000002569 neuron Anatomy 0.000 description 10
- 230000009182 swimming Effects 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 230000006399 behavior Effects 0.000 description 9
- 239000002438 stress hormone Substances 0.000 description 9
- 230000003833 cell viability Effects 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 230000035882 stress Effects 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 239000002858 neurotransmitter agent Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 6
- 239000007995 HEPES buffer Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 235000013402 health food Nutrition 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 5
- 206010029260 Neuroblastoma Diseases 0.000 description 5
- 230000003291 dopaminomimetic effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000012097 Lipofectamine 2000 Substances 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000008366 buffered solution Substances 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 230000009194 climbing Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 4
- 230000003340 mental effect Effects 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000012096 transfection reagent Substances 0.000 description 4
- 208000020401 Depressive disease Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 231100000002 MTT assay Toxicity 0.000 description 3
- 238000000134 MTT assay Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 229960004341 escitalopram Drugs 0.000 description 3
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 2
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 2
- 102000017911 HTR1A Human genes 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000416 anti-micotic effect Effects 0.000 description 2
- 239000012223 aqueous fraction Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000002034 butanolic fraction Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000002038 ethyl acetate fraction Substances 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 241000208422 Rhododendron Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002036 chloroform fraction Substances 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 210000003918 fraction a Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000002044 hexane fraction Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- -1 transdermals Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000011845 white flour Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
図1は、シャシャンボ実抽出物を得る過程を示す。シャシャンボ実2.0kgに蒸溜水30Lを加え、還流抽出機を用いて100℃で温度が上がった後、3時間の間加熱、抽出した。得られた抽出物を減圧フィルタ後、減圧濃縮して107.02gの濃縮液を得た。
図2に図示したように、前記シャシャンボ実の熱水抽出物から系統分画を実施してシャシャンボ実抽出物の分画物(15g)を製造するステップを具体的に説明すると、次の通りである。濃縮液を水で十分に懸濁して2倍体積のヘキサンで1次溶媒移行を3回遂行して水層とヘキサン(hexane) ext.(41.8mg)に分離した。また、水層を2倍体積のクロロホルムで2次溶媒移行を3回遂行してCHCl3ext.(79.9mg)を確保した。エチルアセテートで3次溶媒移行を3回遂行してEtOAc ext.(312.4mg)を確保した。最後に、n−ブタノールで3次溶媒移行を3回遂行してn−BuOH ext.(5g)を確保した。
シャシャンボ抽出物の抗憂鬱効果測定のための実験動物として生後6週齢の雄ICRマウスを(株)サムタコ(SAMTACO、Korea)から購入して動物飼育室で一定の条件(温度:22±2℃、湿度:50±5%、明暗:12時間light/dark cycle)で一週間の間適応させた後、使用した。
雄ICRマウスに本発明のシャシャンボ抽出物を経口投与し、比較群には抗憂鬱剤に使われるエスシタロプラムシュウ酸塩を経口投与した。これらは実験によって6日投与した。
正常な状態で憂鬱症と関連した神経伝達物質であるNEとストレスホルモンであるCORの濃度変化に及ぼす影響は、各薬物6日投与後、マウスから血漿(plasma)を分離してAbnova ELISA kitを使用して製造社の指示に従って測定した。
SH−SY5Y cell(neuroblastoma、human dopaminergic neuronal cell)を1% antimicotics/antibioticsと10%FBSを含有したMEM培地で培養し、96−well plateに細胞数が105cell/mlになるようにシードした後、24時間培養した。
CHO−K1細胞株(Chinese Hamster Ovary Cell)をATCCから購入し、培養液(RPMI 1640、fetal bovine serum 10%、penicilin100IU/ml、streptomycine 100μg/ml)を使用して96−well black wall/clear bottom(BD Falcon)に細胞を分株した後、37℃、5% CO2 インキュベーター(incubator)で24時間培養した。セロトニン1A受容体(5−HT1A receptor)またはセロトニン2A受容体(5−HT2A receptor)各々cDNAをプラスミドトランスフェクション試薬であるlipofectamine 2000を用いて48時間の間細胞内一時的に発現させた細胞を実験に使用した。
CHO−K1細胞株(Chinese Hamster Ovary Cell)をATCCから購入し、培養液(RPMI 1640、fetal bovine serum 10%、penicilin 100IU/ml、streptomycine 100μg/ml)を使用して96−well black wall/clear bottom(BD Falcon)に細胞を分株した後、37℃、5%CO2 インキュベーター(incubator)で24時間培養した。セロトニン2A受容体(5−HT2A receptor)各々cDNAをプラスミドトランスフェクション試薬であるlipofectamine 2000を用いて48時間の間細胞内に一時的に発現させた細胞を実験に使用した。
シャシャンボ実抽出物を有効成分とする免疫増強用薬学的組成物または健康食品組成物は錠剤及びカプセル剤、軟質カプセル剤、顆粒剤、液剤形態に製造できる。更に他の適切な実施形態によると、前記組成物は飲料添加剤に製造することができる。前記免疫増強用薬剤または健康食品は、前記シャシャンボ実抽出物を有効成分として含む組成物が0.01〜99.9重量%で含まれるように散剤、顆粒剤、錠剤、カプセル剤、懸濁液、エマルジョン、シロップ、エアゾール、経皮剤、坐剤、または滅菌注射溶液に剤形化して製造することができる。
図2に図示したように、前記シャシャンボ実の熱水抽出物から系統分画を実施してシャシャンボ実抽出物の分画物を製造するステップを具体的に説明すると、次の通りである。濃縮液を水で十分に懸濁して2倍体積のヘキサンで1次溶媒移行を3回遂行して水層とヘキサン(hexane) ext.(41.8mg)に分離した。また、水層を2倍体積のクロロホルムで2次溶媒移行を3回遂行してCHCl3ext.(79.9mg)を確保した。エチルアセテートで3次溶媒移行を3回遂行してEtOAc ext.(312.4mg)を確保した。最後に、n−ブタノールで4次溶媒移行を3回遂行してn−BuOH ext.(5g)を確保した。
SH−SY5Y cell(neuroblastoma、human dopaminergic neuronal cell)を1% antimycotics/antibioticsと10%FBSを含有したMEM培地で培養し、96−well plateに細胞数が105cell/mlになるようにシードした後、24時間培養した。
CHO−K1細胞株(Chinese Hamster Ovary Cell)をATCCから購入し、培養液(RPMI 1640、fetal bovine serum 10%、penicilin100IU/ml、streptomycin 100μg/ml)を使用して96−well black wall/clear bottom(BD Falcon)に細胞を分株した後、37℃、5% CO2 インキュベーター(incubator)で24時間培養した。セロトニン1A受容体(5−HT1A receptor)またはセロトニン2A受容体(5−HT2A receptor)各々cDNAをプラスミドトランスフェクション試薬であるlipofectamine 2000を用いて48時間の間細胞内一時的に発現させた細胞を実験に使用した。
CHO−K1細胞株(Chinese Hamster Ovary Cell)をATCCから購入し、培養液(RPMI 1640、fetal bovine serum 10%、penicilin 100IU/ml、streptomycin 100μg/ml)を使用して96−well black wall/clear bottom(BD Falcon)に細胞を分株した後、37℃、5%CO2 インキュベーター(incubator)で24時間培養した。セロトニン2A受容体(5−HT2A receptor)各々cDNAをプラスミドトランスフェクション試薬であるlipofectamine 2000を用いて48時間の間細胞内に一時的に発現させた細胞を実験に使用した。
Claims (4)
- シャシャンボ(Vaccinium bracteatum Thunb.)実抽出物を有効成分として含む憂鬱症の予防または改善用健康機能性食品組成物。
- 前記シャシャンボ抽出物は、水、エタノール、メタノール、プロパノール、イソプロパノール、ブタノール、またはこれらの混合物で抽出されたもののうちから選択されるいずれか1つに可溶な抽出物であることを特徴とする、請求項1に記載の憂鬱症の予防または改善用健康機能性食品組成物。
- 請求項1の健康機能食品組成物が0.01〜99.9重量%の量で含まれることを特徴とする、憂鬱症の予防または改善用健康機能性食品。
- 健康機能性食品は、錠剤、カプセル剤、軟質カプセル剤、顆粒剤、及び液剤のうちから選択されるいずれか1つの形態に製造されることを特徴とする、請求項3に記載の憂鬱症の予防または改善用健康機能性食品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021092660A JP2021151245A (ja) | 2016-12-01 | 2021-06-02 | シャシャンボ実の抽出物を含む憂鬱症予防及び改善用健康機能性食品組成物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2016-0162678 | 2016-12-01 | ||
KR1020160162678A KR101799214B1 (ko) | 2016-12-01 | 2016-12-01 | 모새나무 열매 추출물을 포함하는 우울증 예방 및 개선용 건강기능성 식품조성물 |
PCT/KR2017/012586 WO2018101630A1 (ko) | 2016-12-01 | 2017-11-08 | 모새나무 열매 추출물을 포함하는 우울증 예방 및 개선용 건강기능성 식품조성물 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021092660A Division JP2021151245A (ja) | 2016-12-01 | 2021-06-02 | シャシャンボ実の抽出物を含む憂鬱症予防及び改善用健康機能性食品組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019536798A true JP2019536798A (ja) | 2019-12-19 |
JP7189137B2 JP7189137B2 (ja) | 2022-12-13 |
Family
ID=60809245
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019529558A Active JP7189137B2 (ja) | 2016-12-01 | 2017-11-08 | シャシャンボ実の抽出物を含む憂鬱症予防及び改善用健康機能性食品組成物 |
JP2021092660A Withdrawn JP2021151245A (ja) | 2016-12-01 | 2021-06-02 | シャシャンボ実の抽出物を含む憂鬱症予防及び改善用健康機能性食品組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021092660A Withdrawn JP2021151245A (ja) | 2016-12-01 | 2021-06-02 | シャシャンボ実の抽出物を含む憂鬱症予防及び改善用健康機能性食品組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10925914B2 (ja) |
EP (1) | EP3549455A4 (ja) |
JP (2) | JP7189137B2 (ja) |
KR (1) | KR101799214B1 (ja) |
CN (1) | CN110113957A (ja) |
WO (1) | WO2018101630A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101799214B1 (ko) * | 2016-12-01 | 2017-11-20 | 재단법인 전남생물산업진흥원 | 모새나무 열매 추출물을 포함하는 우울증 예방 및 개선용 건강기능성 식품조성물 |
CN110269821A (zh) * | 2019-06-14 | 2019-09-24 | 珠海萱嘉君行健康产业发展有限公司 | 一种含有乌饭树提取物的防腐剂组合物及其制备方法与应用 |
KR102388980B1 (ko) | 2021-04-08 | 2022-04-22 | 재단법인 전남바이오산업진흥원 | 모새나무(Vaccinium bacteaum Thunb.) 잎 추출물을 유효성분을 포함하는 피부 장벽, 보습 개선 및 예방용 화장료 조성물 |
CN114292901B (zh) * | 2021-09-08 | 2023-12-29 | 安徽师范大学 | 一种乌饭树实时荧光定量pcr内参基因的筛选方法 |
KR102388984B1 (ko) | 2021-11-16 | 2022-04-20 | 재단법인 전남바이오산업진흥원 | 모새나무 열매 추출물을 유효성분으로 포함하는 전립선 비대증 예방 또는 치료용 약학조성물 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160025414A (ko) * | 2014-08-27 | 2016-03-08 | 성균관대학교산학협력단 | 모새나무(Vaccinium bracteatum Thunb.) 추출물 또는 이의 분획물을 유효성분으로 포함하는 신경염증 또는 퇴행성 뇌신경 질환의 예방 또는 치료용 약학적 조성물 |
CN105497433A (zh) * | 2014-11-05 | 2016-04-20 | 石友爱 | 一种治疗抑郁症的中药 |
CN105748666A (zh) * | 2016-04-01 | 2016-07-13 | 广州三得医疗科技有限公司 | 一种含艾叶的防治抑郁症和更年期综合症的药物组合物 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100876440B1 (ko) * | 2006-04-27 | 2008-12-29 | 사단법인 우리문화가꾸기회 | 수련 추출물을 포함하는 항스트레스 또는 항우울증 조성물 |
CN101244160A (zh) * | 2007-01-09 | 2008-08-20 | 冯锦和 | 香蕉皮提取物抗应激及抗抑郁的新用途 |
CN101757130B (zh) * | 2008-12-25 | 2013-12-04 | 中国科学院成都生物研究所 | 一种防治抑郁症的药物、其制备方法及用途 |
CN103432184B (zh) * | 2013-09-16 | 2015-01-14 | 延边大学 | 牛蒡子提取物在制药或食品中的应用 |
KR20150113434A (ko) * | 2014-03-28 | 2015-10-08 | 고려대학교 산학협력단 | 인삼씨 추출물을 포함하는 뇌신경세포 보호 및 우울증의 예방, 개선 및 치료용 조성물 |
CN103876236B (zh) * | 2014-04-04 | 2015-08-19 | 江苏九久环境科技有限公司 | 乌饭树果汁及其制备工艺 |
KR101726736B1 (ko) * | 2015-04-03 | 2017-04-17 | 한국식품연구원 | 메밀 싹을 유효성분으로 포함하는 갱년기 또는 폐경기 증상의 예방, 치료 또는 개선용 조성물 |
CN104814995A (zh) * | 2015-05-12 | 2015-08-05 | 沈小玲 | 一种南烛子粉保健品组合物及其制备方法与应用 |
CN105169259A (zh) * | 2015-09-24 | 2015-12-23 | 杨立珍 | 治疗癫狂的方剂及制备方法 |
JP2019529558A (ja) * | 2016-09-21 | 2019-10-17 | マウント デザート アイランド バイオロジカル ラボラトリー | 組織の再生の刺激および促進 |
CN106389785A (zh) * | 2016-10-20 | 2017-02-15 | 丁士彪 | 一种治疗产褥期抑郁症的中药 |
KR101799214B1 (ko) * | 2016-12-01 | 2017-11-20 | 재단법인 전남생물산업진흥원 | 모새나무 열매 추출물을 포함하는 우울증 예방 및 개선용 건강기능성 식품조성물 |
KR101829583B1 (ko) * | 2017-06-01 | 2018-02-20 | 재단법인 전남생물산업진흥원 | 모새나무(Vaccinium bracteatum Thunb.) 잎 추출물을 포함하는 스트레스성 질환 및 우울증 예방 또는 치료용 약학적 조성물 |
-
2016
- 2016-12-01 KR KR1020160162678A patent/KR101799214B1/ko active IP Right Grant
-
2017
- 2017-11-08 JP JP2019529558A patent/JP7189137B2/ja active Active
- 2017-11-08 CN CN201780074485.0A patent/CN110113957A/zh active Pending
- 2017-11-08 WO PCT/KR2017/012586 patent/WO2018101630A1/ko unknown
- 2017-11-08 EP EP17876695.2A patent/EP3549455A4/en active Pending
- 2017-11-08 US US16/465,743 patent/US10925914B2/en active Active
-
2021
- 2021-06-02 JP JP2021092660A patent/JP2021151245A/ja not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160025414A (ko) * | 2014-08-27 | 2016-03-08 | 성균관대학교산학협력단 | 모새나무(Vaccinium bracteatum Thunb.) 추출물 또는 이의 분획물을 유효성분으로 포함하는 신경염증 또는 퇴행성 뇌신경 질환의 예방 또는 치료용 약학적 조성물 |
CN105497433A (zh) * | 2014-11-05 | 2016-04-20 | 石友爱 | 一种治疗抑郁症的中药 |
CN105748666A (zh) * | 2016-04-01 | 2016-07-13 | 广州三得医疗科技有限公司 | 一种含艾叶的防治抑郁症和更年期综合症的药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
EP3549455A1 (en) | 2019-10-09 |
US10925914B2 (en) | 2021-02-23 |
KR101799214B1 (ko) | 2017-11-20 |
JP7189137B2 (ja) | 2022-12-13 |
JP2021151245A (ja) | 2021-09-30 |
EP3549455A4 (en) | 2019-10-09 |
CN110113957A (zh) | 2019-08-09 |
US20190381123A1 (en) | 2019-12-19 |
WO2018101630A1 (ko) | 2018-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019536798A (ja) | シャシャンボ実の抽出物を含む憂鬱症予防及び改善用健康機能性食品組成物 | |
AU2012343872B2 (en) | Vicenin 2 and analogues thereof for use as an antispasmodic and/or prokinetic agent | |
CN104982928B (zh) | 一种红豆杉果保健酵素及其制备方法 | |
CN107846936A (zh) | 蜜蜂可摄取组成物及使用其生产蜂蜜的方法与由此生产的蜂蜜 | |
KR101751398B1 (ko) | 당귀, 산수유, 녹용, 홍삼, 숙지황, 침향 및 벌꿀을 포함하는 항염증 조성물 | |
Liu et al. | Comparative analysis of phytochemical profile, antioxidant and anti-inflammatory activity from Hibiscus manihot L. flower | |
KR101829583B1 (ko) | 모새나무(Vaccinium bracteatum Thunb.) 잎 추출물을 포함하는 스트레스성 질환 및 우울증 예방 또는 치료용 약학적 조성물 | |
CN106659749A (zh) | 包含葎草提取物作为有效成分的用于预防或治疗退行性脑疾病的组合物 | |
KR20150083622A (ko) | 오갈피나무와 뽕나무를 이용한 항비만 조성물 | |
KR101735061B1 (ko) | 개똥쑥 추출물, 아테미시닌 또는 디히드로아테미시닌을 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물 | |
CN102362936B (zh) | 鸡爪芋提取物的用途及其药品和保健品固体制剂、饮料制剂 | |
Nayak et al. | Hypoglycaemic Activity of Chrysobalanus icaco (Fat-pork) Fruit Extract in Diabetes Induced Rats. | |
KR20190006286A (ko) | 오미자 추출물을 유효성분으로 함유하는 염증성 질환 또는 비만 치료 또는 예방용 조성물 | |
KR101470241B1 (ko) | 우울증 예방 또는 치료용 약학적 조성물 | |
KR20100002836A (ko) | 뇌 신경 세포 보호물질을 포함하는 질경이 추출물을포함하는 조성물 | |
KR101854960B1 (ko) | 발아 벼 왕겨 추출물을 유효성분으로 포함하는 항당뇨용 조성물 | |
KR102527907B1 (ko) | 무산상자 추출물을 유효성분으로 포함하는 건선 개선용 조성물 | |
KR101517828B1 (ko) | 홍삼 복합물을 유효성분으로 함유하는 비만 예방, 개선 또는 치료를 위한 조성물 | |
KR20140052580A (ko) | 해조류에서 추출한 후코잔틴을 포함하는 신경보호용 조성물 | |
CN109662986A (zh) | 一种柿叶提取物及其制剂的新医药用途 | |
Banerjee et al. | 3 Ethnobotany, Phytochemistry, and Pharmacological Activity of Marsilea | |
KR20220028260A (ko) | 구멍갈파래 추출물을 포함하는 비만의 개선, 예방 또는 치료용 조성물 | |
KR20230170602A (ko) | 포공영 및 인동등 추출물을 유효성분으로 포함하는 체지방 감소용 조성물 | |
KR20220035764A (ko) | 술패랭이꽃 추출물을 유효성분으로 포함하는 건선 개선용 조성물 | |
CN103695273A (zh) | 一种抗氧化保健酒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190606 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190606 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200623 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200914 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201120 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210202 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20210602 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210602 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20220510 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20220527 |
|
C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20220628 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220920 |
|
C302 | Record of communication |
Free format text: JAPANESE INTERMEDIATE CODE: C302 Effective date: 20220930 |
|
C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20221011 |
|
C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20221108 |
|
C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20221108 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20221201 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7189137 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |